Header and Body 1


Peptide inhibitors of Bfl-1, an anti-apoptotic protein, allow for selective targeting of Bfl-1 dependent cancer cells in therapeutic treatment. Selective peptides may also be used as Bfl-1-detection reagents. This allows for cellular profiling for anti-apoptotic protein dependency, thus potentially acting as a diagnostic tool for stratifying patients.